期刊文献+

舒格利单抗联合培美曲塞和卡铂治疗晚期肺癌患者的临床研究 被引量:2

Clinical efficacy of suglizumab combined with pemetrexed and carboplatin in treatment of advanced lung cancer patients
原文传递
导出
摘要 目的观察舒格利单抗联合培美曲塞和卡铂一线治疗晚期非鳞非小细胞肺癌患者的临床疗效。方法选择2019年7月~2021年12月本院收治的晚期非鳞非小细胞肺癌患者,随机分为试验组与对照组。对照组接受培美曲塞和卡铂一线治疗(第1天静脉滴注500 mg·m^(-2)培美曲塞,第1天静脉滴注5 mg·mL^(-1)·m^(-2)卡铂),试验组在对照组的基础上联合舒格利单抗治疗(第1天滴注200 mg·kg^(-1)舒格利单抗)。21 d为1个周期,每个周期治疗1次。2组患者均治疗至不可耐受药物不良反应或疾病进展。比较2组近期临床疗效、血清细胞角蛋白19片段抗21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)水平,记录药物不良反应发生情况。结果试验组66例,对照组63例。治疗3个周期后,对照组和试验组客观缓解率(ORR)分别为44.44%(28/63)和62.12%(41/62);疾病控制率(DCR)分别为58.73%(37/63)和80.30%(53/62),差异均有统计学意义(均P<0.05)。对照组和试验组血清CYFRA21-1水平分别为(4.23±1.02)和(2.75±0.68)ng·mL^(-1);SCC-A水平分别为(1.54±0.29)和(1.03±0.22)ng·mL^(-1);CEA水平分别为(28.17±4.85)和(9.34±1.76)ng·mL^(-1),差异均有统计学意义(均P<0.05)。试验组和对照组总药物不良反应发生率分别为36.36%(24/66)和33.33%(21/63),差异无统计学意义(P>0.05)。结论舒格利单抗联合培美曲塞和卡铂一线治疗晚期非鳞非小细胞肺癌患者近期疗效确切,可降低肿瘤标志物水平,且安全性良好。 Objective To observe the clinical effect of Suglilizumab combined with pemetrexed and carboplatin in the first-line treatment of advanced non-squamous non-small cell lung cancer in patients.Methods Patients with advanced non-squamous and non-small cell lung cancer admitted to our hospital from July 2019 to December 2021 were randomly divided into experimental group and control group.The control group received first-line treatment with pemetrexed and carboplatin(500 mg·m^(-2)pemetrexed intravenously and 5 mg·mL^(-1)·m^(-2)carboplatin intravenously on the 1st day),and the experimen group received combined treatment with suglizumab on the basis of the control group(200 mg·kg^(-1) suglizumab intravenously on the 1st day).21 d consisted of 1 cycle,and each cycle was treated once.All patients in 2 groups were treated to intolerance of adverse reactions or disease progression.The short-term clinical efficacy,serum cytokeratin 19 fragment anti-21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC-Ag)and carcinoembryonic antigen(CEA)levels were compared between the two groups.The incidence rates of adverse reactions were recorded.Results There were 66 cases in treatment group and 63 cases in control group.After 3 cycles of treatment,the objective remission rate(ORR)of the control group and the experiment group were 44.44%(28/63)and 62.12%(41/62),respectively;the disease control rate(DCR)were 58.73%(37/63)and 80.30%(53/62),respectively,and the difference was statistically significant(all P<0.05).The levels of CYFRA21-1 in control group and experimental group were(4.23±1.02)and(2.75±0.68)ng·mL^(-1),respectively;SCC-A levels were(1.54±0.29)and(1.03±0.22)ng·mL^(-1),respectively;CEA levels were(28.17±4.85)and(9.34±1.76)ng·mL^(-1),respectively,the differences were statistically significant(all P<0.05).The incidence of total adverse drug reactions in test group and control group was 36.36%(24/66)and 33.33%(21/63),respectively,with no statistical significance(P>0.05).Conclusion Suglilizumab combined with pemetrexed and carboplatin in the first-line treatment of advanced non-squamous and non-small cell lung cancer patients has definite short-term efficacy,can reduce the level of tumor markers,and has good safety.
作者 吴志丽 孙雪竹 卢虎生 WU Zhi-li;SUN Xue-zhu;LU Hu-sheng(Department of Oncology,901 Hospital of Joint Logistic Support Force,Hefei 230001,Anhui Province,China)
机构地区 联勤保障部队第
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2023年第16期2302-2305,共4页 The Chinese Journal of Clinical Pharmacology
基金 安徽省自然科学基金资助项目(2008085MH292)。
关键词 舒格利单抗 培美曲塞 卡铂 非鳞非小细胞肺癌 临床疗效 suglizumab pemetrexed carboplatin non-squamous non-small cell lung cancer clinical effect
  • 相关文献

参考文献3

二级参考文献4

共引文献851

同被引文献36

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部